Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Prospect Capital Corporation is an asset management business based in the US. Prospect Capital Corporation shares (PSEC) are listed on the NASDAQ and all prices are listed in US Dollars.
|Latest market close||$8.33|
|52-week range||$4.49 - $8.99|
|50-day moving average||$7.91|
|200-day moving average||$8.19|
|Wall St. target price||$6.50|
|Dividend yield||$0.72 (8.81%)|
|Earnings per share (TTM)||$2.50|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||1.83%|
|1 month (2021-09-22)||5.44%|
|3 months (2021-07-22)||1.09%|
|6 months (2021-04-22)||3.87%|
|1 year (2020-10-21)||63.33%|
|2 years (2019-10-21)||26.79%|
|3 years (2018-10-19)||18.83%|
|5 years (2016-10-21)||4.00%|
Valuing Prospect Capital Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Prospect Capital Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Prospect Capital Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 3x. In other words, Prospect Capital Corporation shares trade at around 3x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Prospect Capital Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.59. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Prospect Capital Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||$632 million|
|Operating margin TTM||65.88%|
|Gross profit TTM||$632 million|
|Return on assets TTM||4.49%|
|Return on equity TTM||27.53%|
|Market capitalisation||$3.2 billion|
TTM: trailing 12 months
There are currently 9.3 million Prospect Capital Corporation shares held short by investors – that's known as Prospect Capital Corporation's "short interest". This figure is 3.8% up from 9.0 million last month.
There are a few different ways that this level of interest in shorting Prospect Capital Corporation shares can be evaluated.
Prospect Capital Corporation's "short interest ratio" (SIR) is the quantity of Prospect Capital Corporation shares currently shorted divided by the average quantity of Prospect Capital Corporation shares traded daily (recently around 1.9 million). Prospect Capital Corporation's SIR currently stands at 4.95. In other words for every 100,000 Prospect Capital Corporation shares traded daily on the market, roughly 4950 shares are currently held short.
However Prospect Capital Corporation's short interest can also be evaluated against the total number of Prospect Capital Corporation shares, or, against the total number of tradable Prospect Capital Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Prospect Capital Corporation's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Prospect Capital Corporation shares in existence, roughly 20 shares are currently held short) or 0.0332% of the tradable shares (for every 100,000 tradable Prospect Capital Corporation shares, roughly 33 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Prospect Capital Corporation.
Find out more about how you can short Prospect Capital Corporation stock.
Dividend payout ratio: 32.43% of net profits
Recently Prospect Capital Corporation has paid out, on average, around 32.43% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 8.8% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Prospect Capital Corporation shareholders could enjoy a 8.8% return on their shares, in the form of dividend payments. In Prospect Capital Corporation's case, that would currently equate to about $0.72 per share.
While Prospect Capital Corporation's payout ratio might seem fairly standard, it's worth remembering that Prospect Capital Corporation may be investing much of the rest of its net profits in future growth.
Prospect Capital Corporation's most recent dividend payout was on 17 November 2021. The latest dividend was paid out to all shareholders who bought their shares by 26 September 2021 (the "ex-dividend date").
Over the last 12 months, Prospect Capital Corporation's shares have ranged in value from as little as $4.4863 up to $8.9873. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Prospect Capital Corporation's is 0.9254. This would suggest that Prospect Capital Corporation's shares are less volatile than average (for this exchange).
Prospect Capital Corporation is a business development company. It specializes in middle market, mature, mezzanine finance, later stage, emerging growth, leveraged buyouts, refinancing, acquisitions, recapitalizations, turnaround, growth capital, development, capital expenditures and subordinated debt tranches of collateralized loan obligations, cash flow term loans, market place lending and bridge transactions. It also makes real estate investments particularly in multi-family residential real estate asset class. The fund makes secured debt, senior debt, senior and secured term loans, unitranche debt, first-lien and second lien, private debt, private equity, mezzanine debt, and equity investments in private and microcap public businesses. It focuses on both primary origination and secondary loans/portfolios and invests in situations like debt financings for private equity sponsors, acquisitions, dividend recapitalizations, growth financings, bridge loans, cash flow term loans, real estate financings/investments. It also focuses on investing in small-sized and medium-sized private companies rather than large public companies. The fund typically invests across all industry sectors, with a particular expertise in the energy and industrial sectors.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.